Senti Bio price target lowered to $2 from $3 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Senti Bio to $2 from $3 and keeps an Equal Weight rating on the shares. Senti Bio reported Q4 results, but the report was "largely uneventful" following the recent pipeline prioritization, said the analyst, who has lowered the firm’s estimate of the odds of success for SENTI-301A in HCC to 10% from 15% previously.